Ipsen: exclusive worldwide licensing agreement with Biomunex
(CercleFinance.com) - Ipsen announces that it has entered into an exclusive worldwide licensing agreement with Biomunex Pharmaceuticals for the BMX-502 program, a bispecific antibody that 'shows particular promise' for treating tumors in mucosal and barrier tissues.
Biomunex will complete the studies required for clinical trial approval in the US, and Ipsen will assume responsibility for Phase I preparatory activities, as well as all future clinical development and global commercialization activities.
Biomunex is eligible for payments of up to $610m, including an upfront payment and clinical development, regulatory and commercial milestone payments, in addition to tiered worldwide royalties on sales.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Biomunex will complete the studies required for clinical trial approval in the US, and Ipsen will assume responsibility for Phase I preparatory activities, as well as all future clinical development and global commercialization activities.
Biomunex is eligible for payments of up to $610m, including an upfront payment and clinical development, regulatory and commercial milestone payments, in addition to tiered worldwide royalties on sales.
Copyright (c) 2024 CercleFinance.com. All rights reserved.